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Abstract
Objective: To evaluate the effectiveness and safety of cannabis/cannabinoids for painful diabetic neuropathy (PDN). 
Design: Systematic review of interventional studies.
Data Source: Medline, PubMed, The Cochrane Central Register of Controlled Trials (CENTRAL), AMED, PsycINFO, 
CINAHL, Web of Science and ScienceDirect, along with references from identified papers and grey literature 
search up to September 2017.  Terms used were combined as follows: (marijuana OR marihuana OR cannabis OR 
cannabinoids) AND (painful neuropathy OR neuropathic pain) AND (Diabetes). 
Study Selection: Studies of cannabis/cannabinoids, in adult participants diagnosed with PDN. Validity of trials was 
assessed using the Cochrane Collaboration’s tool for assessing risk of bias. 
Data Synthesis: Five studies that fit the inclusion criteria were identified. 
Conclusion: Cannabis and cannabinoids provide an interesting treatment choice for PDN. Further high-quality 
studies with larger sample sizes and longer durations are required to assess its long-term effectiveness and safety 
as well as the best form of drug delivery. 
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Introduction 
The mechanism of Diabetic Peripheral Neuropathy 
(DPN) is not fully understood and attempts at identify-
ing the underlying pathophysiology were unsuccess-
ful due to a lack of neurological biomarkers required 
for assessing DPN risk factors (Haanpää and Hieta-
harju, 2013). Currently many conventional treatments 
for painful DPN rely on pharmacotherapy, for example 
mono or combination therapy with antidepressants, 
anticonvulsants or opiates (Cruccu, 2007). Many of 
these pharmacotherapies are considered suboptimal 
and can have unwanted adverse additional effects on 
the recipient (Haanpää and Hietaharju, 2013).  It may 
be that future research can overcome this challenge 
by facilitating a better understanding of the pathogen-
esis of DPN to enable more precise pharmacological 
treatment targets. One such target could be the en-
docannabinoid and cannabinoid receptors (Toth et al., 
2012) renewing interest in the potential use of can-
nabis based agents for managing neuropathic pain. 
Methods  
Why Cannabinoids and Cannabis?
Whereas most current medications for neuropathy act 
upon ion channels, researchers have gained a new 
understanding of the pathophysiology of pain in animal 
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models due to the discovery of endocannabinoids and 
cannabinoid receptors (Toth et al., 2012). Δ9-THC is the 
main psychotropic component of cannabis, which results 
in limiting its therapeutic use as an isolated agent (Gia-
coppo et al., 2014). However, several non-psychoactive 
cannabinoids have been identified, such as cannabidiol 
(CBD) (Earleywine, 2002; and Ben Amar, 2006). Hence, 
cannabinoids is a term used for compounds that mimic 
the effects of Δ9-THC through activating the cannabinoid 
receptors (Chiou et al., 2013). According to numerous 
animal models of pain, THC, its synthetic derivatives and 
CBD have analgesic effects (Mao et al., 2000). Therefore, 
this newfound interest in its therapeutic properties result-
ed in the development of a number of cannabinoid-based 
synthetic medicines (Giacoppo et al., 2014). However, 
there seems to be a dearth in literature investigating the 
extent of clinical significance their side effects might have 
on limiting treatment for neuropathic pain. This warrants 
further robustly constructed research in this area, hence 
the need to evaluate previous clinical trials addressing 
cannabis or cannabinoids as treatment options for the 
management of PDN (Wallace et al., 2015). 
The Research Question 
The following research question was set: ‘What evi-
dence is available regarding the use of cannabis/can-
nabinoids as treatment options for the management of 
PDN in clinical and long term settings?’
Once broken down into a series of relevant but more 
specific objectives, the preliminary aims of conducting 
this systematic review are to evaluate:
• The effectiveness of cannabis/cannabinoids as 
part of the treatment for management of pain in 
patients with PDN. 
• The safety of cannabis/cannabinoids in the treat-
ment of PDN.
Search Strategy
For the purpose of a systematic review, terms used in 
this literature search were combined and the search 
term selected and agreed upon as follows: (marijuana 
OR marihuana OR cannabis OR cannabinoids) AND 
(painful neuropathy OR neuropathic pain) AND (Dia-
betes). 
Figure 1: Literature Review Flowchart 
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Table 1: Literature Review for Systematic Reviews
Databases for Systematic Reviews Date Results Possible Relevant Results 
Database of Abstracts of Reviews of Effects (DARE) 16/05/2017 0 0
Cochrane Database of Systematic Reviews (CDSR) 16/05/2017 2 1
the NIHR Health Technology Assessment (NIHR HTA) 16/05/2017 0 0
National Institute for Health and Clinical Excellence 
(NICE) 16/05/2017 36 0
Evidence for Policy and Practice Information (EPPI) Cen-
tre, which has a database of systematic reviews of public 
health interventions (DoPHER)
16/05/2017 0 0
Scottish Intercollegiate Guidelines Network (SIGN) 16/05/2017 0 0
National Guidelines Clearinghouse (NGC) 16/05/2017 0 0
Table 2: Search Strategy for Grey Literature
Databases for Grey Literature Date Results Possible Relevant Results 
Opengrey.eu 28/05/2017 0 0
WorldCat 28/05/2017 16 8
Opendoar.org 28/05/2017 0 0
Google Scholar 28/05/2017 944 220
Table 3: Inclusion/Exclusion Criteria
Population
Studies of adult participants diagnosed with painful diabetic polyneuropathy and on a 
stable regimen of diabetic therapy. Pre-clinical and animal studies as well as studies con-
cerning children were excluded.
Interventions Cannabis or cannabinoids administered by whichever route of administration (experimental intervention) with any analgesic or placebo (control intervention). 
Outcomes Positive (pain intensity scores, pain relief scores) or adverse health based outcomes. 
Study design
As this area of research is relatively underdeveloped, a systematic review of such a topic 
had to include evidence from studies with a range of designs due to the limited number of 
studies available. 
Language
This systematic review included studies in any language. All results in non-English lan-
guages provided translated abstracts, however (n= 0) of non-English papers met the inclu-
sion criteria for this review. 
Study design
Comparative studies examining the analgesic affects in at least two population groups 
primarily randomised controlled trials (RCTs) and controlled trials. However, if information 
from controlled trials is not available, cohort studies may be included if there is a record of 
data from a comparison group. However, due to the specific population sample, only con-
trolled trials were found and two narrative reviews were identified, which only narratively 
review and do not rank evidence, hence, were excluded.
Settings Hospital wards- rehabilitation centres- nursing and residential respite centres- hospices.
Time frame No limit. 
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Using the review selection criteria, The results from 
multiple electronic databases are presented in Figure 
1 as a flow chart and summarised in Table 1. Finally, 
a manual search of journals and reference lists of the 
selected studies was performed to identify further 
studies (n=1). A search for grey literature was also 
performed (see Table 2).
Assessing Methodological Quality and Data 
Extraction
Study Review: Abstracts returned from the search 
results were independently reviewed by the primary 
researcher to determine whether they satisfied the in-
clusion criteria (Table 3). Uncertainty was resolved by 
consensus with the research team
Data Extraction: Using a standardised data collection 
electronic form summarized in terms of study design, 
participants, method of intervention, and study out-
comes of the included studies in Table 4. 
Risk of Bias (Quality) Assessment: Using the 
Cochrane Collaboration’s tool for assessing risk of 
bias (2008), Table 5 explores heterogeneity, suitability 
of meta-analysis and any flaws in studies which may 
bias the results reported. 
Study Characteristics/Appraisal  
Out of five studies, only one Randomised Controlled 
Trial (RCT) (Wallace et al., 2015) discussed the ef-
ficacy of inhaled cannabis on pain and hyperalgesia of 
patients with PDN. There were 16 participants in the 
Table 4: Studies Included in the Systematic Review
No. Author Date of Pub. Title of Study
Design of 
Study Critical Appraisal Tool Used
1. Hoggart, B. 2015
A multicentre, open-label, 
follow-on study to assess the 
long-term maintenance of 
effect, tolerance and safety of 
THC/CBD oromucosal spray 
in the management of neuro-
pathic pain
Open label 
follow on 
study
The risk of bias assessment 
tool was developed for Co-
chrane (2008), the risk of bias’ 
assessment tool, which con-
siders the results of the trial, 
the validity of the results, and 
whether they can be applied to 
the local population.
2. Toth, C. 2012 
An enriched-enrolment, ran-
domized withdrawal, flexible-
dose, double-blind, placebo-
controlled, parallel assignment 
efficacy study of Nabilone as 
adjuvant in the treatment of 
diabetic peripheral neuropathic 
pain 
Adjuvant 
study
3. Selvarajah, D. 2010
Randomized placebo-con-
trolled double-blind clinical trial 
of cannabis-based medicinal 
product (Sativex®) in painful 
diabetic neuropathy: Depres-
sion is a major confounding 
factor
RCT
4. Wallace, M. S 2015 Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy RCT
5.
GW Pharmaceuti-
cals Ltd. (Principal 
investigator: Solo-
mon Tesfaye)
2012
A Study of Sativex® for Pain 
Relief Due to Diabetic Neu-
ropathy
RCT
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Table 5: Cochrane Collaboration’s Tool for Assessing Risk of Bias
Study
RISK OF BIAS
Random 
Sequence 
Generation
Allocation 
Conceal-
ment
Participant/ 
Personnel 
Blinding
Assessor 
Blinding
Incomplete 
Outcome 
Data
Selective Out-
come Reporting
Outcome 
Overall
Wallace et 
al., 2015 
Low risk of 
bias 
Low risk of 
bias
Low risk of 
bias
Unclear risk 
of bias 
High risk of 
bias High risk of bias
High risk of 
bias
Selvarajah 
et al., 2010
Unclear risk 
of bias
Unclear risk 
of bias
Unclear risk 
of bias
Unclear risk 
of bias
Low risk of 
bias Low risk of bias
Unclear risk 
of bias
GW Phar-
maceuticals 
Ltd., 2012
Unclear risk 
of bias
Unclear risk 
of bias 
Unclear risk 
of bias
Low risk of 
bias
High risk of 
bias Low risk of bias
High risk of 
bias
Hoggart et 
al., 2014
High risk of 
bias
High risk of 
bias 
High risk of 
bias
High risk of 
bias Unclear Unclear risk of bias
High risk of 
bias
Toth et al., 
2012
Low risk of 
bias
Unclear risk 
of bias
Low risk of 
bias
Low risk of 
bias
High risk of 
bias Low risk of bias 
High risk of 
bias
study, all of them being 18 years old and above, and 
presented with PDN. The other four studies (Selvara-
jah et al., 2010; Toth et al., 2012; GW Pharmaceuti-
cals Ltd., 2012; and Hoggart et al., 2014) discussed 
the use of cannabinoids in the management of PDN. 
One study, conducted in Canada (Toth et al., 2012) 
used an oral cannabinoid Nabilone as an adjunctive 
treatment; the selected population sample was speci-
fied (patients with refractory DPN). The total number 
of participants in this study was 37 with an age range 
of 18 or above. The three final studies (Selvarajah et 
al., 2010; GW Pharmaceuticals Ltd., 2012; and Hog-
gart et al., 2014) used (THC/CBD) oromucosal spray 
Sativex® as the intervention method. In total there 
was 389 participants who completed the studies, with 
numbers ranging from 30 to 264 (age range 18 or 
above). Each study employed different methods and 
participant-criteria ranged. Two studies (Selvarajah et 
al., 2010; and GW Pharmaceuticals Ltd., 2012) were 
performed in the UK, while one study (Hoggart et al., 
2014) was performed at clinics in five different coun-
tries (Romania, UK, Canada, Belgium and Czech Re-
public). Out of the five studies, it was unclear whether 
the researchers took into account confounding factors 
in design analysis, except for one RCT (Selvarajah et 
al., 2010).  Additionally, it was unclear whether there 
was follow up long enough to establish long-term ef-
fects of the interventions used except for one study 
(Hoggart et al., 2014). In conclusion, due to the small 
number of studies and the variation in interventions 
and outcomes, pooling of data for meta-analysis was 
inappropriate. Results were therefore reported and 
summarised descriptively. 
Results 
Risk of Bias 
Four trials were judged at high risk of bias, and one 
study at unclear risk of bias (Selvarajah et al., 2010). 
This highlighted several limitations including failure to 
appropriately handle withdrawals, selective outcome 
reporting, and inadequate description of methods of 
randomization, allocation concealment, and blinding 
(Whiting et al., 2015). The major limitations to the find-
ings of this review are the small number of included 
studies, small sample size and short trial durations. 
Moreover, none of the trials provided details of the 
concomitant analgesics taken by their participants 
(except for the study of Hoggart et al., 2015). Further-
more, none of the trials provided evidence to support 
the appropriateness of the sample size.  Therefore, 
in order to reach conclusions regarding the efficacy, 
safety and potential for abuse, trials of longer duration 
with larger sample sizes are needed. 
Effects on Pain 
Only one trial examined the effects of inhaled cannabis 
on PDN (Wallace et al., 2015) and revealed a dose-de-
pendent effect of vaporized cannabis on spontaneous 
pain; therefore, the outcome was positive (P <0.001). 
Four studies examined the effects of cannabinoids 
on PDN. Two of those studies (GW Pharmaceuticals 
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Ltd., 2012; Selvarajah et al., 2010), reported overall 
negative outcomes. The findings of Selvarajah et al. 
(2010) did not exhibit significant differences of reduc-
tion in the two primary outcome measures (change in 
mean daily pain scores and Neuropathic Pain Scale 
scores (P = 0.62; 7.8; -20.1 to 12.1). Furthermore, no 
significant difference in mean change TPS (total pain 
score) at end point between Sativex® and placebo 
was exhibited (P = 0.40; SEM 9.5; 95% CI -11.3 to 
27.8). The study undertaken by GW Pharmaceuti-
cals Ltd. (2012) was never published; however, re-
sults obtained from the website (https://clinicaltrials.
gov) did not report any significant differences between 
Sativex® and placebo on any of the measure out-
comes. Regarding the study by Hoggart et al. (2014), 
234 (70%) participants reported clinically significant 
nerve pain reduction (minimum 30% reduction) and 
also exhibited 50% cumulative improvements in pain 
with time. The authors also concluded that the drug 
is effective since most participants completed the 9 
month trial of treatment with Sativex® without an in-
crease in the number of adjunctive analgesic medica-
tions. Therefore, the overall outcome was positive for 
this study. Toth et al. (2012) reported that reduction 
in pain intensity greater than 30% (ANOVA, P < 0.05) 
and 50% (ANOVA, P = NS) was significantly greater in 
the group receiving flexible dosing of Nabilone com-
pared to the placebo group; hence, this was a positive 
outcome.
Adverse Effects 
Wallace et al. (2015) reported that with the high (7% 
THC) dose cannabis, a significant effect of impaired 
performance on 2 of the 3 neuropsychological tests 
was observed. Euphoria was observed at 100% for 
participants on the high dose of cannabis and at 60% 
for those on placebo. Furthermore, the only group 
of participants that reported a larger percentage of 
somnolence than placebo was the group on high 
(7% THC) dose cannabis (P= 0.018). With respect to 
cognition, the PASAT (Paced Auditory Serial Addition 
Test) tool (Gronwall, 1977) was used to measure atten-
tion and working memory. The majority of the scaled 
score differences were less than 1.5 points lower than 
baseline and no scores below 8 were observed. This 
would indicate that for this group the cognition did not 
decline dramatically into the impaired range. 
In the Hoggart et al. (2014) trial, 78% (n=295) experi-
enced at least one Adverse Effect (AE). 59% (n=224) 
were considered treatment-related and the most com-
monly reported were dizziness (19%), nausea (9%), 
dry mouth (8%), dysgeusia (7%), fatigue (7%), somno-
lence (7%) and feeling drunk (6%). 11% of (n=40) pa-
tients had serious AEs during the study however, only 
1% (n=4) were considered treatment related [amne-
sia (n=2), paranoia (n=1) and suicide attempt (n=1)]. 
There were no significant differences observed in the 
incidence of AEs reported in relation to the patients’ 
mean daily dose. Patients that withdrew from the 
study due to AEs were 23% (7% severe AEs and 18% 
treatment related AEs). However, according to the au-
thors of this study, only a small percentage withdrew 
due to lack of efficacy. 
Toth et al. (2015) reported a number of potentially 
treatment-related AEs including dizziness, dry mouth, 
drowsiness, confusion or impaired memory, lethargy, 
euphoria, headache, and increased appetite. Most 
were considered either mild or moderate. However, in 
the single-blind phase, two participants receiving Na-
bilone at doses of 2 mg daily and 4 mg daily reported 
serious AE (intolerable confusion), which led to their 
discontinuation from the study. In the double-blind 
phase, a total of 46% (n=6/13) of participants receiv-
ing placebo and 54% (n=7/13) of subjects receiving 
Nabilone reported treatment-related AEs. In the study 
of Selvarajah et al. (2010), 6 participants withdrew be-
cause of AEs. However, it was not mentioned whether 
any were treatment related or serious AEs. 
Limitations
Searching for grey literature was challenging due to 
practical issues limiting the inclusion of all studies re-
gardless of publication type/status (CRD, 2009). Con-
ference abstracts and interim results were not consid-
ered due to the difficulty of appraising their quality from 
the minimal detail provided and contacting authors to 
obtain the full details of studies was not possible due 
to time restraints. Moreover, there were two studies 
that were obtained via interlibrary loan not in a read-
able form, which prevented the full text assessment 
during the selection process for this review. 
The first search results highlighted an alternative 
spelling to marijuana “marihuana” which could have 
had an impact on the validity of the data. Since this 
was an identification of a flaw in the search term prior 
to completion of the systematic review, the original 
term had to be altered in order to re-run the searches 
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to ensure that no data was missed shown in Figure 
2. The terms Charas and Hashish are used for a dif-
ferent preparation than marijuana (Earleywine, 2002), 
therefore were excluded in the search term. However 
including them might have provided a larger number of 
relevant search results.
The traditional approach to neuropathic pain manage-
ment has been to classify and treat it based on the ae-
tiology of the underlying pathology. Evidence suggest-
ing the use of a mechanism-based approach when 
classifying neuropathic pain has potential benefits 
such as individualizing therapy and facilitation in test-
ing new therapies (Dworkin et al., 2003). Therefore, 
recruiting participants using a mechanism-based ap-
proach in future clinical trials might yield larger sample 
sizes for future reviews. 
In addition, the number of researchers that performed 
data extraction and quality appraisal was influenced 
Figure 2: Literature Review Flowchart of Modified Search Term 
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by time restrictions. Therefore, the ideal methodology 
had to be adjusted to fit the timeframe and resources 
available for this study, whilst maintaining the robust-
ness. Finally, due to the poor heterogeneity of the 
available retrieved data, no meta-analysis was per-
formed, as this method was not suitable to the types 
of data retrieved during this review.
Discussion and Clinical Implications 
More studies examined the effects of cannabinoids 
(n=4) than inhaled cannabis (n=1). The two pharma-
ceutical preparations of cannabinoids investigated in 
this review are Nabilone (synthetic analogue of THC) 
or Sativex® (THC+CBD). Both have different phar-
macokinetic profiles; Nabilone has a bioavailability of 
60%, whereas the bioavailability of Sativex® is not 
well documented (CPA, 2005). The route of admin-
istration for Sativex® sublingual spray compared to 
the oral route decreases the first-pass metabolism, 
increasing the bioavailability and therefore dose-
titration of the drug (Pryce and Baker, 2005). On the 
other hand, oral cannabinoids such as Nabilone have 
a slower onset of action, lower peak drug concentra-
tions and slow, unpredictable and more erratic ab-
sorption when compared to inhaled cannabis. Moreo-
ver, it was reported that the bioavailability of the drug 
after oral administration varied between individuals. 
This not only indicates that it has an unreliable on-
set of action (Ashton, 2001; and Ben Amar, 2006), 
but also that some individuals are more sensitive to 
the drug via oral administration than others, there-
fore defining a dose may not be standardised for oral 
administration. THC blood concentrations after oral 
route administration were found to be 25-30% of THC 
blood concentrations after smoking an equal dose 
indicating that symptoms are more rapidly relieved 
with inhaled cannabis (Ashton, 2001). However, the 
bioavailability of inhaled cannabis (THC) ranges from 
18 to 50% and has a rapid onset of action (3-5 min) 
(Ben Amar, 2006). Inhaled cannabis also contains 
other substances besides THC, which might facilitate 
an increase in the effects of THC and modulate its 
side effects (Carter et al., 2004). For example CBD 
is known to act synergistically with THC in addition 
to reducing the psychotropic effects of THC (Russo 
and Guy, 2006). Moreover, some experienced pa-
tients prefer inhaled cannabis because it enables 
them to have more control over the appropriate dose 
required to control their symptoms (Abrams et al., 
2003). However, inhaled cannabis in cigarette form 
has more harmful effects than oral administration 
as the long term risk of being affected by pharyn-
gitis, rhinitis, asthma, bronchitis, emphysema and 
lung cancer is greater for marijuana smokers (Hall 
and Solowij, 1998). Moreover, consistency in find-
ings was reported (Haire-Joshu, Glasgow and Tibbs, 
1999) demonstrating smoking for people with diabe-
tes increased the risk for microvascular and macro-
vascular disease and premature mortality. Therefore, 
with the increasing interest in medical cannabis use, 
smoked cannabis seems to be the preferred method 
of administration by patients but cannot be recom-
mended due to the aforementioned co-morbidity 
implications. As a result, interest developed for an 
alternative technique of cannabis inhalation via the 
electric powered vaporization of cannabis without the 
production of potentially toxic products of smoking 
such as tar, carbon monoxide, and other carcinogens 
(Hazekamp et al., 2006). Current trials investigating 
medical marijuana are finding vaporization as an at-
tractive delivery method for research instead of can-
nabis in cigarette form (Wallace et al., 2015). Further-
more, the pharmaceutical industry also has become 
interested in developing and investigating alternative 
formulations of cannabinoids such as smokeless 
oral inhalers (aerosols), nasal sprays (Cannatol Rx, 
2016), transdermal patches (Stinchcomb et al., 2004) 
and rectal suppositories (Brenneisen et al., 1996). 
The longest trial (Hoggart et al., 2014) included in 
this review (a 9-month open-label, follow-on study) 
reported no evidence of the development of toler-
ance towards THC/CBD spray, with the median num-
ber of daily sprays of THC/CBD spray reducing from 
8.0 daily sprays after 1 month of treatment to 6.6 
daily sprays during the last month of treatment. How-
ever, the only included study (Wallace et al., 2015) in-
vestigating the efficacy of inhaled cannabis on PDN, 
was a single dose, short-term study that could not 
provide conclusions regarding the long term toler-
ability, reporting it as an area that requires further re-
search. Therefore, it is apparent that to date, far less 
numbers of controlled trials have been conducted to 
investigate cannabis in the inhaled form. More trials 
of inhaled cannabis may be achieved with access to 
medical grade cannabis for research purposes and 
interest from pharmaceutical companies to include 
this form of cannabis preparation in their research.
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While statistical reduction in pain was reported in three 
studies, a more relevant and important outcome is the 
clinically meaningful pain reduction. This is defined 
as a reduction of 2 points on a 0-10 numerical pain 
scale or 30% reduction in pain intensity (Dworkin et 
al., 2008). Only 2 of the 3 studies reported positive 
findings in this respect. The majority of the included 
studies were placebo-controlled (n=4), however this is 
found to be problematic when investigating drugs with 
psychoactive properties such as cannabis and can-
nabinoids. The study of Selvarajah et al. (2010) was 
able to identify depression as a primary confounder 
affecting its outcomes, which possibly demonstrates 
the strong link of depression with pain perception 
(Frisher et al., 2010).  On the other hand, it was stat-
ed that there was a significant effect of depression 
on Total Pain Score (TPS), which was defined as 
an average score of the following three pain modali-
ties: superficial, deep and muscular pain. However, 
the authors did not provide definitions of these three 
pain modalities or supportive evidence of existing as-
sociation between them and DPN and whether TPS 
was considered as a valid measuring tool for PDN. 
Furthermore, it was not clear in the study whether the 
depression identified was associated with DPN.
The success of blinding in trials largely depends on the 
type and nature of the intervention used (CRD, 2009). 
For interventions such as cannabis, true blinding might 
not be achievable due to its psychoactive effects. The 
two trials with crossover designs (Toth et al., 2012; and 
Wallace et al., 2015) have identified this potential lack 
of blinding. Furthermore, the placebo response in the 
study of Wallace et al. (2015) was reported as larger 
than most trials of painful neuropathy, which suggests 
that the anticipated psychoactive effects might have 
resulted in decrease of pain unrelated to marijuana. 
This in return might affect the outcome and statistical 
analysis of the findings.  It is also important to note that 
since Hoggart et al. (2014) did not include a placebo 
for comparison, the observed maintenance of efficacy 
with the Sativex® spray could be due to other factors 
such as changes in the underlying disease over time, 
changes in the set of participants, and efficacy re-
lated withdrawals.
Furthermore, all studies included did not exclude 
concomitant treatments. Researchers have an ethi-
cal obligation towards participants in their studies, as 
they must avoid causing them harm (beneficence) 
and strive to maximise the possible benefits of the 
research. Therefore, it is unethical to terminate treat-
ments benefitting the patient (National Advisory Coun-
cil on Drug Abuse (NACDA, 2006). However, the use 
of concomitant medications may be a confounding 
factor affecting the results of efficacy and toxicity even 
if the intervention method was proposed for adjunc-
tive use in DPN studies. Therefore, the results pro-
duced might not represent true values. Finally, this 
systematic review did not identify any effectiveness 
studies comparing the outcomes with the traditional 
treatments available for PDN. These types of studies 
would be beneficial in specifying the role that cannabis 
and cannabinoids would have in the management of 
PDN. 
Conclusion
Neuropathic pain is difficult to manage (Commit-
tee for Medicinal Products for Human Use (CHMP), 
2004) and less than 50% of patients receive clinically 
meaningful benefit with the available drugs (Attal et 
al., 2010). Recently, there has been increased inter-
est in investigating the analgesic properties of can-
nabis and cannabinoids on neuropathic conditions, 
and study findings have been consistent and repro-
ducible (Wilsey et al., 2013). Only one trial exam-
ined the effects of inhaled cannabis on PDN (Wal-
lace et al., 2015) with a positive outcome (P <0.001). 
Four studies examined the effects of cannabinoids 
on PDN and two of those studies (Selvarajah et al., 
2010; and GW Pharmaceuticals Ltd., 2012), reported 
overall negative outcomes. It was unclear whether 
there was follow up long enough to establish long-
term effects of the interventions used except for one 
study (Hoggart et al., 2014). Therefore, more robust 
studies with bigger sample sizes are needed to con-
firm these findings, as current evidence on the effects 
and adverse effects of cannabis are minimal. Since 
different preparations of cannabinoids exist for DPN 
and other neuropathic conditions, further large RCTs 
are required to determine the most suitable cannabi-
noid for each neuropathic condition and the most ap-
propriate route of administration in order to maxim-
ise the beneficial effects and minimise the incidence 
of adverse effects. Furthermore, larger randomised 
trials with longer durations and longer term follow 
up are necessary to evaluate the long term effects, 
safety and tolerability of cannabis and cannabinoids 
as analgesics for PDN. Researchers conducting 
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cannabis or cannabinoids trials in the future should 
keep in mind the value of evaluating outcomes that 
are relevant to patients, using standardised outcome 
measures. They should also take into consideration 
the most adequate methods to use to allow appropri-
ate randomisation, blinding, concealment of alloca-
tion and handling of withdrawals to avoid selective 
outcome reporting.
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